Vitamin D, Body Mass Index, and Multiple Sclerosis: Genetic Evidence for Disease Risk and Relapse Hazard
Multiple sclerosis is a chronic immune-mediated disease of the central nervous system in which both genetic susceptibility and environmental exposures contribute to disease onset and progression. In the article “Effects of Vitamin D and Body Mass Index on Disease Risk and Relapse Hazard in Multiple Sclerosis,” Vandebergh, Dubois, and Goris examine two widely discussed modifiable factors: serum 25-hydroxyvitamin D and body mass index. The study is important because it moves beyond asking whether vitamin D deficiency and obesity influence the risk of developing multiple sclerosis, and instead also asks whether these factors affect relapse hazard after disease onset.
Study Design: Mendelian Randomization as a Causal Framework
The authors used Mendelian randomization, a genetic epidemiological method that employs genetic variants as instrumental variables to infer causal relationships between exposures and outcomes. This approach is particularly valuable because genetic variants are fixed at conception and are therefore less vulnerable to reverse causation and many forms of confounding than conventional observational measurements. The investigators used genome-wide association study data for serum 25-hydroxyvitamin D, adult body mass index, multiple sclerosis risk, and relapse hazard in patients with multiple sclerosis.
Vitamin D and Multiple Sclerosis Susceptibility
The findings support a protective causal association between genetically predicted serum 25-hydroxyvitamin D concentrations and multiple sclerosis risk. In the primary analysis using the largest vitamin D genetic instrument set, a one-standard-deviation increase in genetically predicted natural-log transformed 25-hydroxyvitamin D levels was associated with up to a 28% reduction in the odds of multiple sclerosis. This result is consistent with earlier observational and genetic evidence suggesting that insufficient vitamin D status contributes to multiple sclerosis susceptibility.
Body Mass Index and Multiple Sclerosis Risk
The study also found that genetically predicted higher body mass index increased the risk of multiple sclerosis. A one-standard-deviation increase in body mass index, approximately equivalent to 5 kg/m², was associated with a 30% increase in multiple sclerosis risk. This result strengthens the argument that obesity is not merely correlated with multiple sclerosis risk but may contribute causally to disease susceptibility, possibly through inflammatory, metabolic, hormonal, or immune-mediated pathways.
Relapse Hazard: Vitamin D Shows a Distinct Post-Onset Effect
A central contribution of the article is its analysis of relapse hazard after multiple sclerosis onset. The authors found that higher genetically predicted serum 25-hydroxyvitamin D levels were associated with a reduced hazard of relapse. In the primary relapse analysis, a one-standard-deviation increase in genetically predicted vitamin D levels was associated with an approximately 43% lower relapse hazard. The forest plots on page 5 visually reinforce this result, showing a protective direction of effect for vitamin D across several genetic instrument sets.
BMI Does Not Show the Same Relapse Association
In contrast to vitamin D, genetically predicted body mass index was not significantly associated with relapse hazard after disease onset. Although body mass index appeared to influence susceptibility to multiple sclerosis, the evidence did not support a substantial causal role for higher body mass index in determining relapse occurrence. The forest plot on page 6 illustrates this null association, with the confidence interval crossing the null value. This distinction is clinically meaningful because it suggests that risk factors for disease onset and risk factors for disease activity after onset may not be identical.
Interpretation and Clinical Relevance
Overall, the article provides strong genetic evidence that vitamin D and body mass index influence the risk of developing multiple sclerosis, while vitamin D alone appears to influence relapse hazard after onset. These findings have potential implications for prevention, monitoring, and therapeutic research. However, the authors appropriately emphasize that Mendelian randomization estimates lifelong genetically influenced exposure patterns, not the direct effect of short-term supplementation or weight intervention. Consequently, randomized controlled trials remain necessary to determine whether modifying vitamin D status after diagnosis can reliably reduce clinical disease activity in patients with multiple sclerosis.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Vandebergh, M., Dubois, B., & Goris, A. (2022). Effects of vitamin D and body mass index on disease risk and relapse hazard in multiple sclerosis: a mendelian randomization study. Neurology: Neuroimmunology & Neuroinflammation, 9(3), e1165.
